Biotech's bull market, Vertex's gene therapy expansion, and more news from The Readout ...

Companies are being too conservative in how they interpret FDA's AI guidance, but the agency can do more to help, too, Tala ...

CDC leadership continues to try manufacture a scientific debate on vaccines where none exists, writes Ben Lopman.

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter ...

What is urgently needed is a shift from pathogen-specific diagnostics toward pathogen-agnostic diagnostic systems,” write ...

Sources confirm to STAT that Marburg cases have been detected in western Uganda, adding another viral hemorrhagic fever ...

AI giant Anthropic has already become a dominant player in technology and a household name for everyday users of artificial ...

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter: Amylyx ...

Anthropic released Claude Science, an application that optimizes its large language model for scientists and, especially, ...

Demand for alcohol is declining. The industry is fighting harder and more creatively than ever against limits — and winning.

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. David Meek bought Bluebird Bio last year ...

Anthropic will begin developing drugs, BridgeBio pockets a billion, and more biotech news from The Readout ...